Engineering of Δ 9 -tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms

Martín-Banderas, Lucía; Muñoz-Rubio, Inmaculada; Álvarez-Fuentes, Josefa; Durán‐Lobato, Matilde; Arias, José L.; Holgado, M.A.; Fernández‐Arévalo, M.

doi:10.1016/j.colsurfb.2014.09.002

Cited by 28 publications

(31 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The choice of the oily phase was based on the solubility of CBD to easily achieve both high encapsulation efficiencies and drug loading. In this regard, whereas the authors that tried to encapsulate distinct cannabinoids in polymer nanoparticles only achieved encapsulation efficiencies around 70% [15,16,21], those studies that utilized lipid-based carriers exhibited values above 90% [17,22]. This comparison has been corroborated by Durán-Lobato et al [23].…”

Section: Resultsmentioning

confidence: 82%

Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters

Aparicio-Blanco

Sebastián

Benoı̂t

et al. 2019

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

The therapeutic potential of cannabinoids has been truly constrained heretofore due to their strong psychoactive effects and their high lipophilicity. In this context, precisely due to the lack of psychoactive properties, cannabidiol (CBD), the second major component of Cannabis sativa, arises as the phytocannabinoid with the most auspicious therapeutic potential. Hence, the incorporation of CBD in lipid nanocapsules (LNCs) will contribute to overcome the dosing problems associated with cannabinoids.Herein, we have prepared LNCs decorated and loaded with CBD for glioma therapy and screened in vitro their critical parameters. On the one hand, we have encapsulated CBD into the oily core of LNCs to test their in vitro efficacy as extendedrelease carriers against the human glioblastoma cell line U373MG. The in vitro antitumor effect was highly dependent on the size of LNCs due to its pivotal role in the extent of CBD release. Effectively, a comparison between two differently-sized LNCs (namely, 20-nm and 50-nm sized carriers) showed that the smaller LNCs reduced by 3.0-fold the IC 50 value of their 50-nm sized counterparts. On the other hand, to explore the potential of this phytocannabinoid to target any of the cannabinoid receptors overexpressed in glioma cells, we decorated the LNCs with CBD. This functionalization strategy enhanced the in vitro glioma targeting by 3.4-fold in comparison with their equally-sized undecorated counterparts. Lastly, the combination of CBD-loading with CBD-functionalization further reduced the IC 50 values. Hence, the potential of these two strategies of CBD incorporation into LNCs deserves subsequent in vivo evaluation.

show abstract

Section: Resultsmentioning

confidence: 82%

Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters

Aparicio-Blanco

Sebastián

Benoı̂t

et al. 2019

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

show abstract

“…The characteristic bands at 1464 and 1343 cm -1 are associated with the C-H bending. The stretching of C-C-O group appears at 1280 and 1100 cm are attributed to C-O-C group and C-H bond of the methyl group, respectively [32,[34][35][36][37] . The Figure 3c shows the PLGA-PEG spectrum.…”

Section: Resultsmentioning

confidence: 99%

Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin

et al. 2016

View full text Add to dashboard Cite

SbstractOxaliplatin was inserted into polymeric matrices aiming to study the interaction of this drug with these polymers and its capability to diffuse to the environment. Tested polymers were: (1) polyethylene glycol (PEG), (2) poly(lactic-co-glycolic acid) (PLGA), and (3) a copolymer of them (PLGA-PEG). The latter two were synthesized by us using polycondensation in bulk. Oxaliplatin was included in the matrices by the melt mixing process followed by casting. Fourier tran sform infrared spectroscopy (FTIR), proton nuclear magnetic resonance ( 1 H-NMR) and X-ray diffraction (DRX) studies of the polymers were performed proving the obtaining of the desired materials. In addition, the interaction between drug and matrices and the release profile of the oxaliplatin from these matrices were analyzed. Among them, PEG did not control the oxaliplatin release. In turn, PLGA and PLGA-PEG present drug release profiles quite similar. Oxaliplatin was completely released from PLGA and PLGA-PEG in 5 hours, by a relaxation mechanism. There was no evidence of oxaliplatin interaction with the different polymers. In addition, as the PEG improves the biocompatibility and biomasking, obtained results prove the obtaining of a drug release system, which allowed the total use of the drug improving the cancer treatment and even the welfare of the patients.

show abstract

“…Formulation of the γ-Fe 2 O 3 /PLGA (core/shell) particles (of 3:4 γ-Fe 2 O 3 :PLGA weight ratio) was based on the nanoprecipitation solvent evaporation technique, which has been previously used to prepare pure PLGA NPs. 21,75,76 The procedure started with the incorporation of an organic phase containing PLGA and the oleic acid-modified iron oxide nuclei (19 mg, and 14.25 mg in 5 mL of acetone, respectively) to 10 mL of an aqueous solution of PVA (1%, w/v), under sonication (Branson Sonifier 450, Emerson Electric Co., USA). The microtip of the ultrasonic homogenizer was placed into the aqueous phase, leaving 1 cm distance from the bottom of the vial.…”

Section: Introductionmentioning

confidence: 99%

Engineering of stealth (maghemite/PLGA)/chitosan (core/shell)/shell nanocomposites with potential applications for combined MRI and hyperthermia against cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

Engineering of Δ 9 -tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms

Cited by 28 publications

References 49 publications

Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters

Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters

Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin

Engineering of stealth (maghemite/PLGA)/chitosan (core/shell)/shell nanocomposites with potential applications for combined MRI and hyperthermia against cancer

Contact Info

Product

Resources

About